Company Overview and News

4
BHP to sell Cerro Colorado mine to EMR for up to $US320m

59m australianmining.com.au
BHP is to sell its Cerro Colorado copper mine in Chile to Melbourne-based equity firm EMR Capital for $US230 million ($311.4 million) in cash, $US40 million ($US54.2 million) in proceeds and around $US50 million ($67.7 million) in contingent payments down the line, depending on copper performance.
DB

236
Xi can make life tough for US companies after Trump threat

2h malaymail
BEIJING, June 20 — China doesn’t import enough from the US to match Donald Trump’s tariffs dollar for dollar, but President Xi Jinping can still squeeze American companies in other ways in retaliation.
NMR AMPCF DB HYUO NYTAB LOTS HYUD 8604 N33 GM.WS.A BOE GM.WS.B NRSCF AAPL GM.WS.C SBUX HYUP GM BA GM.WSB

21
The TV company behind 'Black Mirror,' part-owned by Fox, has hired banks for a sale

3h cnbc
Endemol Shine Group, the Netherlands-based TV producer of shows including "Black Mirror" and "MasterChef" has hired Deutsche Bank and Liontree to seek a sale, according to people familiar with the matter.
GJV DB NWS NWSA APO.PRB APO.PRA APO

10
TransUnion Completes Acquisition of Callcredit

5h globenewswire
CHICAGO, June 19, 2018 (GLOBE NEWSWIRE) -- TransUnion (NYSE:TRU) announced today that it has completed the acquisition of Callcredit Information Group, Ltd., the second largest and fastest growing consumer credit bureau in the U.K., for approximately £1 billion, or approximately $1.4 billion.
DB TRU

4
There's one Dow stock having a great day: Verizon

11h cnbc
Verizon was the only member of the Dow Jones Industrial Average trading significantly into the green on Tuesday after Deutsche Bank upgraded the wireless provider, saying the shares were relatively cheap.
DB

30
QuinStreet, Ambarella, Amazon, Chevron and Mastercard as Zacks Bull and Bear of the Day

11h zacks
Chicago, IL – June 19, 2018 – Zacks Equity Research highlights QuinStreet (QNST - Free Report) as the Bull of the Day and Ambarella (AMBA - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amazon (AMZN - Free Report) , Chevron (CVX - Free Report) and Mastercard (MA - Free Report) .
HD DB CVX MA AMBA PKD APR APRLY QNST RCKY

358
Banks to Raise Payouts Ignoring Tougher Stress Test

11h zacks
The Fed will be announcing the results of bank stress tests on Jun 21 and results of its Comprehensive Capital Analysis Review ("CCAR") on Jun 28. The tests, which are an annual affair and a must for banks since the 2008 financial meltdown, are designed to ensure that they are in a healthy position to handle crisis during an economic downturn. Looking back, President Donald Trump in May signed the biggest rollback of bank regulations since the global economic downturn into law.
C.WSA BNPQY GS.PRB GS.PRA 83SF GLSSP DBXFF 83SK STI-A UBS.PRDCL MS DBFBF STI.WS.B STI.WS.A CSSLF DBAGF GS.PRJ GS.PRI BNPZY GS.PRD GS.PRC DBZQF GS.PRN DBTMF GS.PRK BCS.PRD DB BCS.PRC DGLD BCS.PRA WFC.PRL WFC.PRJ CS BAC WFC.PRT C.WS.B WFC.PRR DBCBW WFC.PRQ WFC.PRP WFC.PRO C.WS.A WFC.PRN C.PRP DBQFF C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV 47MC C.PRS RY C.PRL VIIX GSC GS.PRICL C.PRJ VIIZ C.PRK BNPQF C.PRG DBZFF GSJ C.PRC CSGKF C.PRPCL TVIX GJS ULSGF DBWQF XIV DBFFF BCS MS.PRE MS.PRF MS.PRG MS.PRA UGLD DBCQF BBT JBK BAC DSLV TFG DBFMF DBWGF RY STI MS.PRI MS.PRK CGBBW WFCNP DBQZF DBWFF GS UBS STI.PRE WFC WFC.WS C BCS.PR DBYQF ZIV USLV

4
JP Morgan's Rob Priestley takes his Oath very seriously

11h theage.com.au
Nobody is suggesting the chairman of JP Morgan’s local operations Rob Priestley has done anything wrong.
DB

4
JP Morgan's Rob Priestley takes his Oath very seriously

11h smh.com.au
Nobody is suggesting the chairman of JP Morgan’s local operations Rob Priestley has done anything wrong.
DB

4
Ashtead Group PLC (ASHTF) CEO Geoff Drabble on Q4 2018 Results - Earnings Call Transcript

12h seekingalpha
Okay. Good morning, and welcome to both those in the room and those watching on the webcast to the Ashtead Group Full-Year's Results Presentation.
DB ASHTY ASHTF AHT

167
3 Stocks to Buy on Weakness | InvestorPlace

12h investorplace
The key to making money by buying stocks low is finding good companies in high-growth sectors whose shares have dropped because of temporary factors. In other words, investors, particularly longer-term investors, should try to find stocks to buy on weakness that will probably prove to be temporary.
FB DB WYNN NEE.PRI NEE.PRJ DQ NEE.PRC TWTR NEE.PRQ NEE.PRR DIS NEE SNAP

27
Bear Of The Day: Ambarella

13h zacks
Ambarella (AMBA - Free Report) is the source of the tech behind the GoPro (GPRO) and super high definition cameras. That said, the company hasn't done that great of job of late in communicating with Wall Street. The most recent quarter was a nice beat, but guidance was below expectations and that sent estimates lower. When estimates fall, the Zacks Rank slides and today AMBA is the Bear Of THe Day.
DB AMBA BIG DAL

11
Deals of the day-Mergers and acquisitions

13h reuters
June 19 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1130 GMT on Tuesday:
IAUGY DB TKOMF AGODY IAG MALRY MIN AGO IAUGF ATLGF 8766 TKOMY MALRF FMI

4
MAGA Rules Everything Around Me

15h seekingalpha
Recently, a reader asked a question about how it's possible to reconcile the Trump administration's trade stance with the Fed's hawkishness in the context of the dollar.
DB

4
RPT-FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019

16h reuters
ALLSCHWIL, Switzerland, June 18 (Reuters) - Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.
DB

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to DB / Deutsche Bank AG on message board site Silicon Investor.

Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Adobe (adbe) opinions
Broadband Wireless Access [WCII, NXLK, WCOM, satellite..] ABWN - Broadband wireless communication systems
UBS - Unique Broadband Systems Broadband u0026 Fiber-Optic Companies to invest in.
XDSL mPhase tech: TV, Broadband Internet u0026 Phone: 1 line! Donny Brascou0027s Goodbye to SI!
STO AV/DB Workshop Adaptive Broadband (NASDAQ:ADAP)
CUSIP: D18190898